Shares in Mylan (NSDQ:MYL) dropped -3% to $40.46 apiece today after the FDA rejected its Abbreviated New Drug Application for the generic version of GlaxoSmithKline‘s (NYSE:GSK) Advair Diskus.
The Canonsburg, Penn.-based company said it is “in the process of reviewing this response and will provide an update on its application as soon as practicable once it has completed its review and discussed the FDA’s feedback with the agency.”
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan shares down -3% after FDA rejects Advair generic appeared first on MassDevice.
from MassDevice http://ift.tt/2nMyCsY
Cap comentari:
Publica un comentari a l'entrada